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Blood–brain barrierThere is increasing recognition of the importance of blood–brain barrier (BBB) disruption in aging, dementia,
stroke and multiple sclerosis in addition to more commonly-studied pathologies such as tumors. Dynamic
contrast-enhancedMRI (DCE-MRI) is amethod for studying BBB disruption in vivo.We review pathologies stud-
ied, scanning protocols and data analysis procedures to determine the range of available methods and their suit-
ability to different pathologies. We systematically review the existing literature up to February 2014, seeking
studies that assessed BBB integrity using T1-weighted DCE-MRI techniques in animals and humans in normal
or abnormal brain tissues. The literature search provided 70 studies that were eligible for inclusion, involving
417 animals and 1564 human subjects in total. The pathologies most studied are intracranial neoplasms and
acute ischemic strokes. There are large variations in the type of DCE-MRI sequence, the imaging protocols and
the contrast agents used. Moreover, studies use a variety of different methods for data analysis, mainly based
on model-free measurements and on the Patlak and Tofts models. Consequently, estimated KTrans values varied
widely. In conclusion, DCE-MRI is shown to provide valuable information in a large variety of applications, rang-
ing from common applications, such as grading of primary brain tumors, tomore recent applications, such as as-
sessment of subtle BBB dysfunction in Alzheimer3s disease. Further research is required in order to establish
consensus-based recommendations for data acquisition and analysis and, hence, improve inter-study compara-
bility and promote wider use of DCE-MRI.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
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that line brain capillaries and are sealed by tight junctions. Astrocytes, pericytes,microglial
cells and basement membranes interact with the endothelium of the BBB, providing
functional and structural support.1. Introduction
The blood–brain barrier (BBB) separates the parenchyma of the cen-
tral nervous system from the blood. Quantitative information about the
functional integrity of the BBB can be gained by performing dynamic
contrast-enhanced MRI (DCE-MRI). DCE-MRI has proven valuable in
the assessment of many brain pathologies that cause an opening of
the BBB, such as tumors (Singh et al., 2007), multiple sclerosis (Jelescu
et al., 2011) and acute ischemic strokes (Kassner et al., 2009). While
these diseases show relatively large abnormalities in BBB functionality,
there is also growing interest in the application of DCE-MRI to patholo-
gies associatedwithmore subtle and chronic BBB disruption, such as ce-
rebral small vessel disease (Wardlaw et al., 2008;Wardlaw et al., 2009),
diabetes (Starr et al., 2003) and Alzheimer3s disease (Starr et al., 2009).
Although DCE-MRI has been widely used to study pathological
changes in BBB functionality, studies differ in their MR imaging pro-
cedures and have been performed using a variety of different MRI
sequences, contrast agents and time courses. Furthermore, there is
no standard method for analyzing the data. Established analysis
approaches include relatively simple non-model based methods
(Topakian et al., 2010) as well as a range of pharmacokinetic models
(Tofts, 1991). Several previous reviews have focused on speciﬁc applica-
tions such as oncology (Türkbey et al., 2010; Jain, 2013; Barnes et al.,
2012) and on methodological aspects of DCE-MRI (Sourbron and
Buckley, 2012, 2013); as far as we are aware, there are no reviews
that cover the application of DCE-MRI in aging, microvascular disease
or dementia. The aim of this work is to provide an overview of all appli-
cations and scanning protocols used in DCE-MRI of the brain by
performing a systematic review of the literature. First, we describe the
important components of the BBB and available permeability models,
then review available data on BBB permeability imaging. Furthermore,
we aim to identify the most commonly used methods for data analysis
and provide an overview of the resulting parameter ranges.
2. Background
2.1. Blood–brain barrier functionality
The BBB is formed by endothelial cells that line brain capillaries and
are sealed by tight junctions, which are unique to the brainmicrovascula-
ture. The endothelium of the BBB interacts with several cellular and
non-cellular elements, such as astrocytes, pericytes, microglial cells
and basement membranes, that provide both functional support and
structural support to the BBB (Abbott and Friedman, 2012; Obermeier
et al., 2013). Together they form an interactive cellular complex, the
‘neurovascular unit’ (NVU). A schematic drawing of the NVU is shown
in Fig. 1. The BBB regulates the passage of essential molecules such as glu-
cose, while restricting the diffusion of potentially harmful substances.
Many brain pathologies are known to cause a disruption of the BBB.
The mechanisms that cause BBB opening are many and differ between
diseases. In meningitis, for example, damage to the BBB is initiated by
extrinsic systemic factors, such as infections and autoimmune process-
es. Other diseases, including Alzheimer3s disease and ischemic stroke,
are thought to activate intrinsic cellular mechanisms secondary to
the neuroinﬂammatory injury and other as yet unknown processes(Rosenberg, 2012). Several comprehensive reviews provide detailed in-
formation on themolecular biology of BBB disruption in disease (Abbott
and Friedman, 2012; Obermeier et al., 2013; Rosenberg, 2012).
2.2. Measurement of blood–brain barrier disruption using DCE-MRI
Disruption of the BBB can enable the extravasation of low-molecular
weight MRI contrast agents. This accumulation of contrast material in
the extravascular extracellular space (EES) of affected tissues leads to
increased longitudinal relaxation rate and, therefore, increased signal
intensity in T1-weighted images. DCE-MRI exploits this T1 enhance-
ment in order to detect and evaluate regions of BBB disruption. The
DCE-MRI procedure typically consists of intravenous injection of con-
trast agent followed by the repeated acquisition of T1-weighted images
(see Fig. 2), providing measurements of signal enhancement as a func-
tion of time. The enhancement kinetics can be used to extract quantita-
tive or semi-quantitative information regarding BBB integrity.
MR signal changes caused by contrast agent extravasation are deter-
mined by several factors, including tissue perfusion and capillary per-
meability. In the brain, DCE-MRI is considered to be the standard MRI
approach for assessing permeability, while dynamic susceptibility con-
trast MRI (DSC-MRI) is the method of choice for perfusion imaging
(Sourbron and Buckley, 2013). However, it has been shown that DCE-
MRI can combine perfusion and permeability measurements by using
a sufﬁciently long acquisition time (to capture slow interstitial uptake)
with high temporal resolution early on (to capture the ﬁrst pass of the
contrast bolus) (Li et al., 2000; Li et al., 2012; Sourbron et al., 2009;
Larsson et al., 2009).
2.3. Analysis of DCE-MRI data
Different approaches have beenused to analyzeDCE-MRI data, rang-
ing from relatively simple visual assessment of enhancement curves to
more complex ﬁtting to pharmacokinetic models. Heuristic analysis of
the signal enhancement curves provides semi-quantitative measures
Fig. 2. Illustration of DCE-MRI in a patientwith a glioma. The repeated acquisition of T1-weighted images after contrast agent injection allows the calculation of signal enhancement as a function
of time (middle) when compared to the pre-contrast signal intensity (left). These curves can be used to calculate maps of quantitative pharmacokinetic parameters (e.g. KTrans, right).
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maximum enhancement. Such measurements are easy to obtain but dif-
ﬁcult to interpret (Budde et al., 2012). Quantitative analysis on the other
hand aims to provide a link between the tissue signal enhancement and
physiologically relevant parameters such as microvascular permeability,
blood ﬂow, blood volume fraction and interstitial volume fraction.
In order to relate the measured signal enhancement to the contrast
agent concentration, an appropriate signal model is required. While
early DCE-MRI studies assumed a linear relationship between signal en-
hancement and contrast uptake, it is well known that the signal en-
hancement is highly dependent on intrinsic tissue and acquisition
parameters (Armitage et al., 2005; Armitage et al., 2011). Consequently,
more complex approaches were developed in order to control for the
effect of tissue characteristics such as the pre-contrast longitudinal re-
laxation time and the longitudinal and transverse relaxivities of the con-
trast agent (Armitage et al., 2005).
Pharmacokinetic modeling was ﬁrst introduced for the analysis of
DCE-MRI in the early 1990s by Brix et al. (1991), Larsson et al. (1990),
and Tofts (1991), followed by a consensus paper on the notation
(Tofts et al., 1999). Since then, improvement of the imaging techniques
(e.g. higher temporal resolution and contrast-to-noise ratio) and a bet-
ter understanding of the underlying physiology have promoted the de-
velopment of several more complex pharmacokinetic models. Detailed
reviews of tracer kinetic modelling approaches in DCE-MRI have been
published by Sourbron and Buckley (2012, 2013). In the following, we
will brieﬂy describe a basic tissue model and the three most commonly
used pharmacokinetic models in DCE-MRI.
Fig. 3A displays a general tissue model with exchange of contrast
agent between blood plasma and the EES. Target parameters of
pharmacokinetic modeling in DCE-MRI are the fractional plasma
volume vp, the fractional interstitial volume ve, the plasma ﬂow Fp
and the permeability-surface area product PS, which measures the rate
at which contrast agent particles leak out of the plasma and into the EES
per unit tissue volume and plasma concentration. An important physio-
logical parameter that is widely reported in DCE-MRI studies is the vol-
ume transfer constant KTrans, which is the rate at which contrast agent is
delivered to the EES per volume of tissue and contrast agent concentra-
tion in the arterial blood plasma. While the terms PS and KTrans are some-
times used interchangeably in the literature, PS represents the clearance
for contrast agent leaking from the capillary plasma into the EES, i.e. the
ﬂux of contrast agent across the BBB normalized to the tissue plasma con-
centration and tissue volume; in contrast, KTrans (as implicitly deﬁned by
Tofts et al., 1999), is the contrast clearance normalized to the arterial
plasma concentration and therefore depends on the plasma ﬂow Fp sup-
plying the capillaries in addition to PS (the mathematical form of this re-
lationship is model-dependent). KTrans is necessarily equal to the productof plasma ﬂow Fp and the extraction fraction E (i.e. the fraction of contrast
agent molecules that leak into the EES).
Most pharmacokinetic models require the arterial input function
(AIF) to be known, which describes the tracer concentration in blood
plasma over time. There are several strategies for determining the AIF
(Calamante, 2013), including the use of a standard function (Weinmann
et al., 1984), experimentally derived population-averaged AIFs (Parker
et al., 2006) and simultaneous individual measurement of the AIF in a
feeding vessel close to the tissue of interest (Sourbron et al., 2009).
The conventional Tofts model (Tofts, 1991) considers isodirectional
ﬂux of tracer between the two well-mixed blood plasma and EES
compartments with the volume transfer constant KTrans. The plasma
compartment is assumed to have negligible volume (vp ≈ 0), which
makes the classic Tofts model a one-compartment model for weakly
vascularized tissues. This model is illustrated in Fig. 3B and character-
ized by the working Eq. (1):
CtðtÞ ¼ KTrans ∫
t
0
CpðτÞexp½−
KTransðt−τÞ
ve
dτ; ð1Þ
where Cp(t) is the AIF.
Tofts et al. extended their classic model by introducing the blood
plasma as a second well-mixed and highly perfused compartment
(Tofts et al., 1999; see Fig. 3C). In addition to the two parameters KTrans
and ve, the model allows the fractional plasma volume vp to be estimated
and, hence, separates enhancement effects due to contrast leakage from
those due to intravascular contrast:
CtðtÞ ¼ vpCpðtÞ þ KTrans ∫
t
0
CpðτÞexp½−
KTransðt−τÞ
ve
dτ: ð2Þ
If themodelﬁts thedatawellwith a non-negligible vp value, then the
tissuemust be highly perfused (Fp=∞) and the system is permeability-
limited with KTrans = PS (Sourbron and Buckley, 2013).
Finally, the Patlak model also describes a highly perfused two-
compartment tissue but considers unidirectional transport from the
blood plasma into the EES (see Fig. 3D). The tracer concentration in tis-
sue is given by
CtðtÞ ¼ vpCpðtÞ þ KTrans ∫
t
0
CpðτÞdτ: ð3Þ
When ﬁrst introducing this approach, Patlak and colleagues
proposed a linear graphical analysis method, which is often used as it
Fig. 3. Schematic illustrations of common pharmacokineticmodels and target parameters.
The exchange between the extravascular extracellular space (EES, volume fraction ve) and
capillary blood plasma (volume fraction vp) is determined by the plasma ﬂow Fp and the
permeability-surface area product PS. (A) Generic tissue model. (B) Conventional Tofts
model (with negligible blood volume and volume transfer constant KTrans). (C) Modiﬁed
Tofts model with non-negligible blood compartment. (D) Patlak model with non-
negligible plasma compartment and one-way transport of contrast agent across the BBB.
For the latter two models, it may be assumed that KTrans = PS for any solution ﬁtting the
data well with a non-negligible vp.
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regressed against ∫
t
0
CpðτÞdτ=CpðtÞ, yielding a straight line with slope
KTrans and y-intercept vp.
3. Methods
3.1. Search strategy
The existing literature was systematically reviewed up to Febru-
ary 2014 by performing an electronic search in PubMed, EMBASE,
MEDLINE and Web of Knowledge databases. Multiple combinations
of the following search terms were used: ‘permeability’, ‘brain’,
‘blood–brain barrier’, ‘MRI’, ‘dynamic’, ‘DCE-MRI’ and ‘contrast en-
hancement’. English as well as non-English literature was sought.
The electronic search was supplemented by hand searching the ref-
erence lists of review papers.
One reviewer performed the primary literature search, removed du-
plicates and screened all papers3 titles and abstracts in order to identify
those relevant for full assessment. Before ﬁnal inclusion or exclusion of
studies, a second reviewer continued the search, read the full text of the
selected articles, extracted the relevant data and performed the analysis.
Disagreements between reviewers about inclusion or exclusion of
papers were resolved through discussion with a third reviewer. The
third, fourth and ﬁfth reviewers complemented the search and assisted
with the data analysis.
3.2. Eligibility criteria
We sought studies which assessed BBB integrity using dynamic
contrast-enhanced MRI techniques. We included studies on humans
and animals in all diseases known or thought to affect BBB function.
Consequently, we excluded other applications of DCE-MRI such as
breast or prostate cancer aswell as publications that focus on theoretical
aspects of image processing or modelingwithout testing them in a clin-
ical setting (e.g. Gal et al., 2008). Furthermore, we accepted only prima-
ry research articles which were available as full-text, but checked
review articles for additional primary references.
We excluded studies using non-dynamic MRI methods, DSC-MRI or
non-MRI methods in order to decrease variability between studies,
which is already considerable between DCE-MRI studies. The literature
search yielded several papers that focused on therapeutic BBB disrup-
tion for novel anti-cancer drugs. Since these mainly addressed pharma-
ceutical or technical aspects of the disruption method on a molecular
level, these studies were rejected. An excellent review on DCE-MRI in
clinical trials of antivascular therapies can be found in O3Connor et al.
(2012). However, we did include studies that focused on the clinical ef-
fect of treatment strategies and its link with BBB disruption if they pro-
vided baseline DCE-MRI parameters. Moreover, we rejected single case
reports and articles inwhich substantial information about theMRI pro-
cedure or the data analysis was lacking.
3.3. Data extraction and analysis
One reviewer independently extracted the data from each in-
cluded study and cross-checked information with preliminary ex-
tracted data. Disagreements were resolved by consensus. We
noted the studied disease or pathology, sample size and subjects3
ages (in the case of human studies). Moreover, we extracted details
of the DCE-MRI protocol, noting scanner ﬁeld strength, MRI se-
quence with repetition time (TR) and echo delay time (TE), ﬁeld of
view, matrix size, slice thickness, overall duration and temporal res-
olution. Extracted data also included the type and dose of contrast
agent and the injection protocol. Furthermore, we noted whether
post-processing techniques were applied prior to data analysis, the
analysis method used and the tissues/locations analyzed. Where
Fig. 4. Flow diagram summarizing the literature search and inclusion process.
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main study purpose and the overall conclusion of the study.
In consequence of the large heterogeneity of included studies, qual-
ity assessment using standardized criteria as recommended in Guyatt
et al. (2008) was difﬁcult. However, we extracted limitations of the
methodology where stated and whether any patients had been imaged
but then excluded from further analysis, so as to assess the feasibility
and applicability of the technique.
4. Results
4.1. Systematic literature search results
The electronic search yielded 829 results, 31 of which were in non-
English languages. After removing duplicates, 352 publications were
further analyzed for inclusion (see Fig. 4). After scanning abstracts and
titles, we excluded studies using non-dynamic and non-MRI methods
(n= 179). We also excluded review papers (n= 46), technical proto-
cols (n = 2) and DSC-MRI studies (n = 38), leaving 87 articles for
full-text assessment. At this stage, we identiﬁed 29 studies that were
not relevant to the focus of this review. Moreover, we excluded confer-
ence abstracts thatwere not detailed enough for full data extraction and
that had not subsequently been published in full (n = 8), single-case
reports and publications with missing information on the imagingmethodology (n = 2) and duplicate publications (n = 1). In addition
to the resulting 47 relevant DCE-MRI studies, 23 relevant articles were
identiﬁed by hand searching the bibliographies of review papers. Over-
all, the full literature search to February 2014 provided 70 DCE-MRI
studies that were eligible for inclusion in this review, published
between February 1990 (Kermode et al., 1990) and December 2013
(Cramer et al., 2014).4.2. Subjects and sample sizes
Table 1 summarizes themain study sample characteristics and scan-
ning protocols related to each pathology. Of the 70 included studies, 17
used animals (i.e. rodents (Budde et al., 2012; Abo-Ramadan et al.,
2009; Ali et al., 2010; Durukan et al., 2009; Ewing et al., 2003; Ferrier
et al., 2007; Nagaraja et al., 2010; Taheri et al., 2009; Hoff et al., 2012;
Krueck et al., 1994; Li et al., 2010; Noseworthy and Bray, 2000;
Quarles et al., 2012; Aryal et al., 2014; Brandt et al., 2008), apart from
one study of beagle dogs (Su et al., 1998) and one of rabbits (Wei
et al., 2011)). The sample size was not made available in one of these
publications (Ewing et al., 2003). The mean sample size of the remain-
ing animal studies was 25 animals, with a total number of 417 animals
(including 19 healthy controls; 336/417 were rodents). The largest in-
cluded study involved 113 rats (Abo-Ramadan et al., 2009), whereas
Table 1
Study sample characteristics and scanning protocols related to pathology. ‘Mean age’ displays the average of study mean ages for studies investigating the same pathology.
Pathology Sample Scanning protocol References
Subjects Number of studies Number of subjects Mean age (years) Median imaging duration (min) Median temporal resolution (sec)
Intracranial neoplasms Humans 30 716 48.4 5.5 5.3 Singh et al. (2007); Li et al. (2000); Li et al. (2012);
Sourbron et al. (2009); Larsson et al. (2009);
Larsson et al. (1990); Haris et al. (2008a,c);
Thompson et al. (2012); Miyati et al. (1997);
Awasthi et al. (2012); Roberts et al. (2000);
Bagher-Ebadian et al. (2012); Manuchehri et al.
(2007); Cao et al. (2009); Cha et al. (2006); Chu
et al. (2012); Harrer et al. (2004); Ludeman et al.
(2002); Lüdemann et al. (2009); Lüdeman et al.
(2000); Mills et al. (2009); Provenzale et al.
(2006); Zhu et al. (2000); Ferl et al. (2010); Jia
et al. (2013); Larsen et al. (2013); Wilkinson et al.
(2006); Zhang et al. (2012); Larsson et al. (2013)
Animals 8 140 − 15.0 11.5 Budde et al. (2012); Ali et al. (2010); Ferrier et al.
(2007); Hoff et al. (2012); Krueck et al. (1994); Li
et al. (2010); Quarles et al. (2012); Aryal et al.
(2014)
Stroke / cerebrovascular disease Humans 11 482 65.9 9.0 14.0 Kassner et al. (2009); Wardlaw et al. (2008);
Wardlaw et al. (2009); Topakian et al. (2010);
Armitage et al. (2011); Aksoy et al. (2013);
Vidarsson et al. (2009); Kassner et al. (2005);
Thornhill et al. (2010); Taheri et al. (2011a,b)
Animals 5 154 − 25.0 150.0 Abo-Ramadan et al. (2009); Durukan et al. (2009);
Ewing et al. (2003); Nagaraja et al. (2010); Taheri
et al. (2009)
Multiple sclerosis Humans 8 186 41.3 21.8 34.8 Jelescu et al. (2011); Larsson et al. (1990);
Kermode et al. (1990); Cramer et al. (2014); Taheri
et al. (2011b); Gaitán and Shea (2011); Shinohara
et al. (2011); Ingrisch et al. (2012)
Pneumococcal meningitis Animals 1 42 − n/a n/a Brandt et al. (2008)
Zinc deﬁciency Animals 1 36 − 36.0 240.0 Noseworthy and Bray (2000)
Neurocysticercosis Humans 1 35 n/a 3.0 5.7 Gupta et al. (2012)
Traumatic head injuries Animals 1 30 − 7.5 15.0 Wei et al. (2011)
Alzheimer3s disease Humans 1 30 73.7 34.4 229.0 Starr et al. (2009)
Multiple system atrophy Humans 1 29 59.0 6.0 7.7 Song et al. (2011)
Infective brain lesions Humans 1 26 26.6 2.8 5.3 Haris et al. (2008a)
Mild cognitive impairment Humans 1 22 47.0 6.8 25.5 Wang et al. (2006)
Diabetes Humans 1 20 68.2 90.0 900.0 Starr et al. (2003)
Brain tuberculomas Humans 2 18 23.2 2.8 5.3 Singh et al. (2007); Haris et al. (2008b)
Normal aging Animals 1 15 − 12.0 15.0 Su et al. (1998)
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268 A.K. Heye et al. / NeuroImage: Clinical 6 (2014) 262–274two studies used a sample size smaller than ten (Ferrier et al., 2007; Li
et al., 2010).
The remaining 53 studies were in humans, including 1564 subjects
in total (163 of which were healthy controls). The mean sample size
for human studies was 27. Only one study involvedmore than 100 sub-
jects (Haris et al., 2008a) and six studies were based on fewer than ten
humans (Jelescu et al., 2011; Larsson et al., 1990; Kermode et al., 1990;
Thompson et al., 2012).
Information regarding patient age was not provided in seven of the
53 studies (Li et al., 2000; Li et al., 2012; Sourbron et al., 2009; Larsson
et al., 1990; Aksoy et al., 2013; Miyati et al., 1997; Awasthi et al.,
2012). A further seven publications stated only the age range of the
study subjects (Awasthi et al., 2012; Haris et al., 2008b; Roberts et al.,
2000; Vidarsson et al., 2009; Bagher-Ebadian et al., 2012; Kassner
et al., 2005; Manuchehri et al., 2007). Mean age as stated in the remain-
ing 39 human studies was highly dependent on the studied pathology,
ranging between 9 years (Thompson et al., 2012) (pediatric brain tu-
mors) and 74 years (Wang et al., 2006) (mild cognitive impairment).
4.3. Pathologies studied
The majority of animal studies concerned intracranial neoplasms
(Budde et al., 2012; Ali et al., 2010; Ferrier et al., 2007; Hoff et al.,
2012; Krueck et al., 1994; Li et al., 2010; Quarles et al., 2012; Aryal
et al., 2014) including a total of 140/417 animals. Five publications in-
vestigated changes in the BBB caused by induced focal cerebral ischemia
in 154/417 animals overall (Abo-Ramadan et al., 2009; Durukan et al.,
2009; Ewing et al., 2003; Nagaraja et al., 2010; Taheri et al., 2009).More-
over, one study each focused on the inﬂuence of pneumococcal menin-
gitis (Brandt et al., 2008), normal aging (Su et al., 1998), zinc deﬁciency
(Noseworthy and Bray, 2000) or traumatic head injuries (Wei et al.,
2011) on the BBB.
The pathology most studied in humans was intracranial neoplasms
(30 publications, 716/1564 subjects), including primary brain tumors
and brain metastases (Li et al., 2012; Sourbron et al., 2009; Larsson
et al., 2009; Larsson et al., 1990; Haris et al., 2008a,c; Thompson et al.,
2012; Miyati et al., 1997; Awasthi et al., 2012; Roberts et al., 2000;
Bagher-Ebadian et al., 2012; Manuchehri et al., 2007; Cao et al., 2009;
Cha et al., 2006; Chu et al., 2012; Harrer et al., 2004; Ludemann et al.,
2002; Lüdemann et al., 2009; Lüdemann et al., 2000; Mills et al., 2009;Fig. 5. Summary of contrast agents, contrast agent doses and MRI sequences. The bar
height indicates the number of studies using a particular method, subdivided by
pathology.Provenzale et al., 2006; Zhu et al., 2000; Ferl et al., 2010; Jia et al.,
2013; Larsen et al., 2013; Wilkinson et al., 2006; Zhang et al., 2012).
Eleven studies investigated changes in BBB integrity caused by stroke
and/or cerebrovascular disease (Kassner et al., 2009; Wardlaw et al.,
2008; Wardlaw et al., 2009; Topakian et al., 2010; Armitage et al.,
2011; Aksoy et al., 2013; Vidarsson et al., 2009; Kassner et al., 2005;
Thornhill et al., 2010; Taheri et al., 2011a,b) with a total of 482/1564
subjects. Eight studies focused on multiple sclerosis (Jelescu et al.,
2011; Larsson et al., 1990; Kermode et al., 1990; Cramer et al., 2014;
Taheri et al., 2011b; Gaitán and Shea, 2011; Shinohara et al., 2011;
Ingrisch et al., 2012) including a total of 186/1564 subjects. Other pa-
thologies included Alzheimer3s disease (Starr et al., 2009), mild cogni-
tive impairment (Wang et al., 2006), brain tuberculomas (Singh et al.,
2007; Haris et al., 2008b), infective brain lesions (Haris et al., 2008a),
multiple system atrophy (Song et al., 2011), diabetes (Starr et al.,
2003) and neurocysticercosis (Gupta et al., 2012).
4.4. Blood–brain barrier changes in disease
Thirteen of the 70 included studies aimed to investigate the correla-
tion between a particular disease and BBB dysfunction. For this purpose,
BBB disruptionwas quantiﬁed in order to test for a signiﬁcant difference
between diseased subjects and healthy controls. Signiﬁcant differences
compared to control subjects or healthy tissuewere found in eight stud-
ies, investigating acute ischemic stroke (Abo-Ramadan et al., 2009),
pneumococcal meningitis (Brandt et al., 2008), brain metastases
(Budde et al., 2012), multiple system atrophy (Song et al., 2011), type-
II diabetes (Starr et al., 2003), vascular cognitive impairment (Taheri
et al., 2011a), normal-appearing and lesion tissue in multiple sclerosis
patients (Cramer et al., 2014; Taheri et al., 2011b), mild cognitive im-
pairment (Taheri et al., 2011b), zinc deﬁciency (Noseworthy and Bray,
2000) and small vessel disease (Topakian et al., 2010). Moreover, Starr
et al. observed differences in signal intensity proﬁles over time between
Alzheimer3s disease patients and controls (Starr et al., 2009). Increased
BBB disruption without statistical signiﬁcance was observed in patients
with mild cognitive impairment (Wang et al., 2006). Su et al. showed a
non-signiﬁcant increase in BBB permeability with normal aging in bea-
gle dogs (Su et al., 1998).
16 studies performed DCE-MRI in order to distinguish between
different types or grades of pathology. Seven of those studies showed sta-
tistical signiﬁcance that DCE-MRI derived parameters differentiate prima-
ry brain tumor types and grades (Roberts et al., 2000; Ludemann et al.,
2002; Lüdemann et al., 2000; Mills et al., 2009; Zhu et al., 2000; Jia et al.,
2013; Zhang et al., 2012). Furthermore, signiﬁcant differences were
found between infective vs. neoplastic brain lesions (Haris et al., 2008a),
asymptomatic vs. symptomatic neurocysticercosis (Gupta et al., 2012),
severe and moderate vs. mild traumatic brain injuries (Wei et al., 2011),
and radiationnecrosis vs. tumor recurrence (Larsen et al., 2013).Wardlaw
et al. showed that post-contrast signal enhancement was higher in cere-
brospinal ﬂuid and white matter in lacunar (i.e. small vessel disease
stroke) than in cortical (i.e. large artery atherothromboembolic stroke)
patients (Wardlaw et al., 2008; Wardlaw et al., 2009). Kassner et al.
found signiﬁcantly different permeability scores between stroke patients
who proceeded to hemorrhage and those who did not with and without
thrombolytic therapy (Kassner et al., 2009; Kassner et al., 2005). Further-
more, Aksoy et al. (2013) reported signiﬁcantly differentDCE-MRI param-
eters for hemorrhagic strokes depending on their size and location.
4.5. Contrast agent and dose
The type and dose of contrast agents used in the included publica-
tions are summarized in Fig. 5. In most studies, the contrast agent
used was Gd-DTPA (gadopentetate dimeglumine, 45/70 studies) or its
variant Gd-DTPA-BMA (gadodiamide, 15/70 studies), given as an intra-
venous bolus injection. In 31 studies, this contrast agent was given in
the standard dose of 0.1 mmol/kg body weight. However, delivered
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(Ferrier et al., 2007). Ten studies delivered a ﬁxed quantity of contrast
agent, ranging between 7.5 mmol (Kassner et al., 2009; Vidarsson
et al., 2009; Thornhill et al., 2010) and 20 mmol (Wardlaw et al.,
2008; Wardlaw et al., 2009; Armitage et al., 2011) in humans. Single
studies employed different gadolinium-based agents such as Gd-DOTA
(gadoterate meglumine) (Li et al., 2000; Chu et al., 2012), gadobutrol
(Gd-BT-DO3A) (Jelescu et al., 2011; Cramer et al., 2014; Wilkinson
et al., 2006; Ingrisch et al., 2012; Song et al., 2011; Larsson et al.,
2013), gadoteriol (Thompson et al., 2012) and albumin-labeled Gd-
DTPA (Ali et al., 2010). We did not ﬁnd any study that investigated the
inﬂuence of different contrast agent types or concentrations, though
Abo-Ramadan et al. state that different doses lead to an increase or de-
crease in signal-to-noise ratio (Abo-Ramadan et al., 2009).4.6. Scanning techniques and ﬁeld strength
The MRI pulse sequence types used are summarized in Fig. 5. The
technique most frequently used was a spoiled gradient echo sequence
(27 studies) and its ultra-fast variants (18 studies). Further protocols in-
clude 11 other gradient recalled echo sequences (Kassner et al., 2009;
Larsson et al., 2009; Budde et al., 2012; Abo-Ramadan et al., 2009;
Durukan et al., 2009; Hoff et al., 2012; Quarles et al., 2012; Kassner
et al., 2005; Cao et al., 2009; Thornhill et al., 2010; Larsson et al.,
2013), six spin-echo methods (Larsson et al., 1990; Kermode et al.,
1990; Taheri et al., 2009; Krueck et al., 1994; Noseworthy and Bray,
2000; Su et al., 1998) and two unspeciﬁed T1-weighted imaging se-
quences (Starr et al., 2003; Song et al., 2011). Furthermore, two studies
used a TOMROP (T-One by Multiple Read-Out Pulses) pulse sequence
(Ewing et al., 2003; Nagaraja et al., 2010), two studies used T1mapping
of partial inversion recovery (TAPIR) (Taheri et al., 2011a,b), and one
study each used a THRIVE (Wei et al., 2011), RF-FAST (Wang et al.,
2006) and TWIST (Jia et al., 2013) sequence.
Four publications focused on introducing new scanning methods. A
scanning procedure for combined and consecutive DSC- and DCE-MRI
measurement was introduced by Miyati et al. (1997) and Thompson
et al. (2012) respectively. Moreover, Jelescu et al. (2011) and Li et al.
(2012) presented a dual-temporal resolution scanning method with
high temporal resolution during the bolus ﬁrst pass and high spatial
resolution during the later phase.
Themajority of human studies (35/53) were performedwith amag-
netic ﬁeld strength of 1.5 T, while 16 studies used a 3 T scanner; one
study each was performed using a 0.5 T (Kermode et al., 1990) and aFig. 6. Data analysis methods used in the included studies. Numbers indicate the count of
studies using the particular method. (Note that some studies used more than one approach.
Consequently, the numbers of studies do not add up to the 70 included studies.).1.9 T scanner (Starr et al., 2003). A wider range of magnetic ﬁeld
strengths from 1.5 T (Krueck et al., 1994) to 11.75 T (Li et al., 2010)
were found in animal studies, with the majority of studies using 4.7 or
7 T scanners. Two studies did not provide this information (Li et al.,
2012; Wei et al., 2011).
4.7. Duration and temporal resolution of DCE-MRI
The duration of data collection following contrast injection varied
widely with values from 2.1 min (Miyati et al., 1997) to 155 min
(Shinohara et al., 2011). The median DCE-MRI imaging durations (not
stated in ﬁve publications (Larsson et al., 1990; Li et al., 2010; Brandt
et al., 2008; Chu et al., 2012; Provenzale et al., 2006)) according to pa-
thology studied are shown in Table 1, together with themedian tempo-
ral resolution (not stated in three publications (Brandt et al., 2008; Chu
et al., 2012; Provenzale et al., 2006)). The highest temporal resolution of
1 s was found in tumor studies (Larsson et al., 2009; Quarles et al.,
2012), whereas one study on diabetes used the longest intervals, in
the range of 10–30 min (Starr et al., 2003).
Vidarsson et al. (2009) and Larsson et al. (2013) investigated the in-
ﬂuence of the temporal resolution and/or overall scan timeon the quan-
tiﬁcation of BBB disruption, ﬁnding that reducing the overall scanning
time and sampling with a lower temporal resolution result in increased
uncertainty of the pharmacokinetic parameters KTrans, ve and vp. As
shown in Table 1, the overall scanning duration and the temporal reso-
lution vary signiﬁcantly between applications. In general, the highest
temporal resolution is used in brain tumors. This is necessary to mea-
sure the fast kinetics typically seen in malignant neoplasms, but may
limit spatial resolution and coverage. Conversely, studies that assess
tissues with slow leakage rates (e.g. healthy appearing tissue in MS
patients, aging or dementia) often use lower temporal resolutions that
allow for better spatial resolution and coverage.
4.8. Use of post-processing techniques
42 of the 70 included studies (60%) did not report the use ormethod
of image post-processing. Themost commonly used technique reported
was image registration, aligning the DCE-MRI images to a pre-contrast
acquisition and/or anatomic images, in order to remove patient move-
ment (Jelescu et al., 2011; Kassner et al., 2009; Wardlaw et al., 2008;
Wardlaw et al., 2009; Starr et al., 2003; Starr et al., 2009; Topakian
et al., 2010; Budde et al., 2012; Armitage et al., 2011; Taheri et al.,
2009; Haris et al., 2008a,b,c; Aksoy et al., 2013; Lüdemann et al., 2009;
Zhu et al., 2000; Ferl et al., 2010; Zhang et al., 2012; Thornhill et al.,
2010; Taheri et al., 2011a; Gaitán and Shea, 2011; Shinohara et al.,
2011; Larsson et al., 2013). Several studies reported a lack of precision
of quantitative values due to limited spatial resolution or poor signal-
to-noise ratio (Kassner et al., 2009; Ferrier et al., 2007; Cha et al.,
2006; Gaitán and Shea, 2011), but only four studies report the use of
image processing techniques for noise reduction, including Gaussian
smoothing (Lüdemann et al., 2009), Kalman ﬁltering (Taheri et al.,
2011a,b) and unspeciﬁed smoothing of the signal enhancement curves
(Ferl et al., 2010). In addition, three studies corrected DCE-MRI data
for scanner signal intensity drift using phantoms. Only one study inves-
tigated the effect of scanner noise and drift on signal enhancement data
(Armitage et al., 2011), concluding that studies should investigate and if
necessary correct for these inﬂuences in order to prevent systematic
errors.
4.9. Data analysis methods and pharmacokinetic models
A wide variety of approaches to data analysis were used in the in-
cluded studies (Fig. 6). Model-free methods included the visual assess-
ment of spatiotemporal enhancement patterns in multiple sclerosis
lesions (Kermode et al., 1990; Gaitán and Shea, 2011; Shinohara et al.,
2011), calculation of semi-quantitative parameters from the signal
Table 2
KTrans values reported for different tissue types and pharmacokinetic models. Given values are the median [range] of reported study sample means from human (in black) and animal
(in orange) studies. Please note that some subjects included in these studies (e.g. high grade glioma patients) underwent treatment before entering the study. Hence, the reported baseline
parameters might be inﬂuenced by interventions that were not the focus in the study.
KTrans (·10-2 min-1)Pathology
Normal appearing tissue
Mixed gray and white matter
White matter
Gray matter
Tumor tissue
Mixed
Glioma
Meningeoma
Astrocytoma
Stroke lesion 
Ischemic
Hemorrhagic
Multiple sclerosis lesion
Neurocysticercosis
Tuberculoma
Infective lesion
Traumatic injury
Conventional Tofts
−
−
−
6.00
[-0.37 - 25.00]
16.60
[2.00 - 124.00]
37.40
[27.80 - 47.00]
14.30
[2.80 - 111.00]
−
−
2.23
[0.92 - 3.53]
3.50
[2.00 - 5.00]
242.50
[204.00 - 281.00]
210.00
−
Modified Tofts
0.40/1.70
[0.30 - 0.50]/[0.40 - 3.00]
1.60
−
34.00
7.95/12.60
[1.90 - 21.40]/[2.09 - 13.80]
−
−
−
−
−
−
−
−
3.80
[0.19 - 4.90]
Patlak
0.39/0.03
[0.00 - 0.06]
0.20
[0.04 - 0.84]
0.08
[0.05 - 0.89]
−
3.10/0.97
[1.20 - 3.60]
−
−
0.84/0.35
[ 0.15 - 0.41]
−
−
−
−
−
−
Other
0.01
[0.00 - 0.32]
0.04
−
−
0.70/6.25
[1.70 - 13.00]
−
−
1.94
[0.78 - 3.10]
5.50
0.98
−
−
−
−
270 A.K. Heye et al. / NeuroImage: Clinical 6 (2014) 262–274enhancement (Wardlaw et al., 2008; Wardlaw et al., 2009; Starr et al.,
2003; Starr et al., 2009; Topakian et al., 2010; Brandt et al., 2008; Su
et al., 1998; Miyati et al., 1997; Wang et al., 2006; Mills et al., 2009;
Provenzale et al., 2006; Wilkinson et al., 2006) and/or contrast agent
concentration (Budde et al., 2012; Armitage et al., 2011) curves, and
model-free deconvolution (Singh et al., 2007; Larsson et al., 2009;
Cramer et al., 2014; Haris et al., 2008a,c; Awasthi et al., 2012; Ferl
et al., 2010; Larsen et al., 2013; Gupta et al., 2012). The most commonly
used pharmacokinetic models were the conventional Tofts model
(Singh et al., 2007; Jelescu et al., 2011; Li et al., 2000; Noseworthy and
Bray, 2000; Haris et al., 2008a,b,c; Thompson et al., 2012; Manuchehri
et al., 2007; Cha et al., 2006; Harrer et al., 2004; Zhu et al., 2000; Ferl
et al., 2010; Jia et al., 2013; Gupta et al., 2012), the modiﬁed Tofts
model (Li et al., 2012; Ali et al., 2010; Hoff et al., 2012; Aryal et al.,
2014; Wei et al., 2011; Awasthi et al., 2012; Bagher-Ebadian et al.,
2012; Cao et al., 2009; Chu et al., 2012; Harrer et al., 2004; Zhang
et al., 2012; Ingrisch et al., 2012; Song et al., 2011; Larsson et al.,
2013), the Patlak model (Larsson et al., 2009; Cramer et al., 2014;
Abo-Ramadan et al., 2009; Durukan et al., 2009; Ewing et al., 2003;
Nagaraja et al., 2010; Taheri et al., 2009; Krueck et al., 1994; Vidarsson
et al., 2009; Bagher-Ebadian et al., 2012; Larsen et al., 2013; Thornhill
et al., 2010; Taheri et al., 2011a,b) and a simpliﬁed approach based on
the Patlak model (Kassner et al., 2009; Ferrier et al., 2007; Aksoy et al.,
2013; Roberts et al., 2000; Kassner et al., 2005) as introduced by
Shames et al. (1993) and Iannotti et al. (1987). Other modeling ap-
proaches included a variant of the conventional Tofts model that con-
siders only the ﬁrst pass of the contrast bolus (Li et al., 2000; Harreret al., 2004), a two-compartment exchange (Sourbron et al., 2009;
Larsson et al., 2009) and uptake (Sourbron et al., 2009; Ingrisch et al.,
2012) model, and a modiﬁed two-compartment exchange model that
includes two EES compartments (one in slow and one in fast exchange
with the blood compartment) (Ludemann et al., 2002; Lüdemann et al.,
2009; Lüdemann et al., 2000). Furthermore, one study each applied an
AIF-free reference region model introduced by Yankeelov et al. (2005)
in rat gliomas (Quarles et al., 2012) and a shutter-speed model consid-
ering three-site equilibrium water exchange (Li et al., 2010). Table 2
summarizes the range of KTrans estimates for different tissue types and
pharmacokinetic models as reported in the included publications.
Several studies aimed primarily at comparing different approaches
for data analysis. Li et al. (2000) introduced a variant of the conventional
Tofts model that only considers the ﬁrst pass of the contrast bolus. They
evaluated this method in n = 11 patients with primary brain neo-
plasms, ﬁnding that the results were visually comparable with those
of the conventional Tofts model but less noisy and less susceptible to
large vessel contributions. Harrer et al. (2004) evaluated the same
model in n = 18 patients with high-grade gliomas, reporting a good
correlation with the modiﬁed Tofts model but no correlation with the
conventional Tofts method, though it should be noted that the AIFs
used differed between the models due to software limitations. Values
obtained with the conventional Tofts model were considerably higher,
indicating an overestimation of quantitative parameters due to vessel
contributions. Larsson et al. (2009) used simulated data in order to in-
vestigate the accuracy of the two-compartment exchange and Patlak
models. As expected, they found that the Patlak method is accurate for
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provides more accurate results for high KTrans values (Larsson et al.,
2009). Li et al. (2010) considered the effect of water exchange, ﬁnding
the Patlakmodel to signiﬁcantly underestimate the fractional blood vol-
ume when compared to their three-site equilibrium shutter-speed
model. A non-parametric method for evaluating DCE-MRI in n=16 gli-
oma patients was presented by Ferl et al. (2010),who showed that their
resulting parameters closely approximate the conventional Tofts model
parameters. Finally, Bagher-Ebadian et al. (2012) presented a method
for quantifying BBB disruption in heterogeneous glioblastoma based
on a voxel-by-voxel selection from a set of nested models: the most
complexmodelwith three parameterswas required to ﬁt the data in re-
gions of aggressive tumor growth, while simpler models predominated
in less aggressive tumor portions and in healthy tissues.
5. Discussion
Our systematic review of the literature revealed 70 studies involving
methods to assess BBB disruption in 15 pathologies in 417 animals and
1564 humans. These studies showed considerable heterogeneity with
regard to image acquisition and analysismethods. This is partly a conse-
quence of the wide range of tissues, pathologies and study objectives.
For example, tumor studies used higher temporal resolution and shorter
imaging duration on average compared with studies of less permeable
tissue such as multiple sclerosis, ischemic stroke and normal appearing
brain. However, it should be noted that a minority of the articles explic-
itly justiﬁed the methodology used. The factors inﬂuencing inter-study
comparability and implications for futures studies are discussed in the
following paragraphs.
5.1. Inter-study comparability of quantitative DCE-MRI parameters
Due to the wide range of analysis techniques used and their strong
dependence on underlying assumptions and acquisition parameters, a
lack of inter-study comparability represents a major problem. Care
must be taken when comparing results from different studies as
shown by thewide parameter ranges in Table 2. Some of this variability
is inevitable due to the heterogeneity of the study populations (e.g. sub-
jects' age) and study designs. Sincemost articles did not explicitly justify
the analytical method employed, differences in the choice of pharmaco-
kinetic model may account for some of the variation. Biased parameter
estimates are likely to be obtained when the assumptions of the model
are not met in the tissue or when the data acquired are inadequate
to determine a unique solution. For example, several studies (e.g. Ali
et al., 2010, Zhang et al., 2012) apply the same model to tumor tissue
and contralateral healthy tissue, although the underlying tissue phy-
siology is very different and onemodel is unlikely to be valid in both sit-
uations. The importance of appropriate model selection has been
demonstrated both theoretically (Sourbron and Buckley, 2011) and ex-
perimentally in gliomas (Harrer et al., 2004) and low-permeability brain
tissue (Larsson et al., 2009; Cramer and Larsson, 2014) and is discussed
further in Section 5.2. Several additional factors may also inﬂuence the
results of DCE-MRI studies.
Firstly, the calculation of contrast agent concentration from signal
enhancement requires reliable estimation of intrinsic tissue parameters
such as the pre-contrast longitudinal relaxation time T10. There are sev-
eral methods of estimating T10, with variable ﬂip angle (Brookes et al.,
1999) and variable saturation time delay (Larsson et al., 1988) being
themost common. The effect of uncertainty in T10 estimation on the cal-
culation of contrast agent concentrations has been investigated by
Schabel and Parker (Schabel and Parker, 2008). They demonstrate that
T10 produces a signiﬁcant concentration bias, which shows the impor-
tance of accounting for T10 when assessing BBB disruption in different
tissue types (Armitage et al., 2011). It should also be noted that, unless
T1 is measured at each time point, drifts in signal intensity may intro-
duce further errors in pharmacokinetic parameters; as noted above,the issue of scanner stability was seldom addressed in the included
articles.
Secondly, most pharmacokinetic models require the AIF to be
known. Hence, determination of AIF represents a key issue in the reli-
able estimation of pharmacokinetic parameters. As mentioned above,
there are several strategies for AIF selection and the optimal method
varies according to pathology, study aims and clinical requirements
(Calamante, 2013). In most applications, direct measurement of the
AIF is generally considered preferable to standard or averaged AIFs
(Lavini and Verhoeff, 2010). However, this method is not always possi-
ble and is susceptible to partial volume and in-ﬂow artefacts; uncertain-
ty remains regarding which vessel should be sampled and how, with
approaches ranging from manual region of interest selection to
methods for automatic vessel detection (Chen et al., 2008). There is
also disagreement on whether to describe the capillary bed in terms of
blood concentration or plasma concentration by correcting for the he-
matocrit (Hct). In the latter case, Hct should ideally be determined for
every subject, but a standard value such as Hct = 0.45 is often assumed
(Sourbron and Buckley, 2013). In theory, all model equations and
resulting parameter values can easily be converted between conven-
tions. However, several studies did not report this and other details, im-
peding reliable comparison of parameter values from different studies.
Other sources of uncertainty rarely considered in DCE-MRI studies
may arise due to a lack of available data. For example, relaxivity values
speciﬁc to a contrast agent, ﬁeld strength and tissue/pathology are rare-
ly known, with the consequence that uniform relaxivity across tissues
and compartments is generally assumed. A further common assump-
tion is that of fast water exchange between compartments; the inﬂu-
ence of restricted water exchange has been described in the literature
(see 100 and references therein) but models accounting for this effect
have received relatively little attention.
5.2. Implications for future DCE-MRI studies of BBB disruption
Given the diversity of DCE-MRI applications in the brain, it is impos-
sible to prescribe a universal “recipe” for future studies, though at-
tempts have been made to better standardize methodology and
reporting (Tofts et al., 1999; DCE MRI Technical Committee, 2012;
Leach et al., 2012). Instead, it is essential to recognise that the optimal
method is highly dependent on the speciﬁc application. An extensive
body of primary DCE-MRI literature and a number of excellent review
articles should help to facilitate optimal study design in the future. In
the following paragraphs we discuss some of the key aspects of acquisi-
tion protocol design and data analysis. In addition to these technical as-
pects, it should be noted that the overall design of a study (e.g. large
sample size, appropriate control group) will be particularly important
given the limitations of present DCE-MRI methods. We recommend
that for most applications, changes in the longitudinal relaxation rate
rather than signal intensity should be measured, since the former
more accurately reﬂects contrast agent concentration, required for
quantitative pharmacokinetic analysis. A range of pulse sequences are
available to obtain this data, and the optimal choice may be a compro-
mise between speed, accuracy, spatial coverage and other factors. Two
of the most critical acquisition parameters to determine are the tempo-
ral resolution and total duration of the scan, since the optimal values de-
pend on the nature of the tissue being investigated and the quantities to
be measured (Sourbron and Buckley, 2012). For example, temporal res-
olution of the order of a second is required to quantify tissue plasma
ﬂow; even if this quantity is of no interest, it may be necessary to ac-
count for ﬂow in order to accurately assess permeability. The likely in-
ﬂuence of blood ﬂow may be determined using computer simulations,
providing plausible tissue parameter ranges are available and relevant
to the subjects and tissues being studied (Sourbron et al., 2009;
Larsson et al., 2009). Temporal resolution must also be set against re-
quirements for spatial resolution and coverage, which differ markedly
between applications (e.g. focal vs. diffuse pathology). For accurate
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ration should be long enough for signiﬁcant contrast extravasation to
occur: this may be on the order of a few minutes in tissues such as
brain tumors, but longer scans are required in less permeable tissues
such as normal-appearing brain. If the EES volume fraction ve is to be ac-
curately measured then imaging should continue well into the “wash-
out” phase, when the EES contrast agent concentration begins to fall.
Further research is needed to investigate how variations in contrast
agent types and doses affect pharmacokinetic parameters.
A wide range of pharmacokinetic models have been proposed for
ﬁtting DCE-MRI data, the most popular of which divide the tissue into
well-mixed compartments. It is essential to recognize the assumptions
built into these models and to assess their likely validity for a given ap-
plication (Sourbron and Buckley, 2013). The original Toftsmodel, for ex-
ample, is strictly valid only in weakly vascularized tissues, where
contrast agent in the capillaries can be neglected; furthermore, the
ﬁtted KTrans is equal to PS only when the blood ﬂow is sufﬁciently
high. For tissues where the vascular contribution is signiﬁcant, the
Patlak or extended Tofts models may be more appropriate, provided
again that plasma ﬂow is high. The choice of model should also reﬂect
the MRI protocol: if the acquisition duration is short and BBB leakage
is slow then models that do not allow back-diffusion (e.g. Patlak and
tissue-uptake models) may be suitable, while application of a model
that does include back-diffusion (e.g. extended Tofts model) can result
in increased uncertainty in the ﬁtted parameters. Similarly, application
of a model that includes ﬂow (e.g. tissue-uptake and two-compartment
exchange models) is counterproductive if the acquired temporal resolu-
tion is insufﬁcient. These and other considerations have been investigated
theoretically by Sourbron and Buckley (2011) and are summarized
accessibly in their recent review (Sourbron and Buckley, 2013). A recent
investigation by Cramer et al. further emphasized the importance of ap-
propriate model selection in the context of subtle BBB permeability
(Cramer and Larsson, 2014). If it is unclear which model to select a-priori
then data-driven approaches, e.g. use of Akaike information criteria, can
be used to determine the most suitable model (Ewing and Bagher-
Ebadian, 2013), although this does not guarantee that themodel assump-
tions are met.
As most current data apply to tumors, more data are required for
assessing low-level BBB abnormalities. The relative lack of methodolog-
ical assessments to determine the best methods of measuring low level
BBB disruption in normal or abnormal appearing brain in aging, demen-
tia or brain microvascular disease, argue for substantially more work to
determine the optimum contrast and dose, acquisition parameters, and
data analysis methods.6. Conclusion
This systematic review has highlighted the wide range of applica-
tions where DCE-MRI has been used to assess BBB integrity. We found
large variations in studied pathologies, MRI procedures and data analy-
sis methods resulting in widely varying estimates of permeability pa-
rameters. Nevertheless, DCE-MRI has been shown to provide valuable
information in a growing ﬁeld of applications, ranging from the grading
of primary brain tumors to the assessment of healthy-appearing tis-
sue in multiple sclerosis patients or dementia. In methodological
terms, DCE-MRI is a relatively mature technique, but the lack of
agreed standards for image acquisition, data modeling and study
reporting hinders inter-study comparison and meta-analysis. Im-
proved reliability of DCE-MRI, especially in subtle permeability
states, is required. Where feasible, further technical development
should be accompanied by attempts to establish consensus-based
recommendations for data acquisition and analysis in order to im-
prove inter-study comparability and promote wider use of DCE-
MRI both clinically and in research (Tofts et al., 1999; DCE MRI Tech-
nical Committee, 2012; Leach et al., 2012).Acknowledgments
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